

**CD19**  
**Catalog # PVGS1921****Specification**

---

**CD19 - Product Information**

Primary Accession [P15391-1](#)  
**Species**  
Human

**Sequence**  
Pro20-Lys291

**Purity**  
> 95% as determined by Bis-Tris PAGE  
> 95% as determined by HPLC

**Endotoxin Level**  
Less than 1EU per µg by the LAL method.

**Expression System**  
HEK293

**Theoretical Molecular Weight**  
60.1 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).**

**Reconstitution**  
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.

**Storage & Stability**  
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

**CD19 - Additional Information**

**Target Background**  
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.

**CD19 - Protein Information**

## **CD19 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## **CD19 - Images**